Suppr超能文献

癌胚抗原、组织多肽抗原和神经元特异性烯醇化酶的胸膜水平用于通过判别分析对小细胞肺癌和非小细胞肺癌患者进行分类。

Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis.

作者信息

Paone G, De Angelis G, Greco S, Fiorucci F, Bisetti A, Ameglio F

机构信息

Department of Cardiovascular and Respiratory Sciences, La Sapienza University, Rome, Italy.

出版信息

J Cancer Res Clin Oncol. 1996;122(8):499-503. doi: 10.1007/BF01187163.

Abstract

The classification of lung cancer into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) is essential for disease prognosis and treatment. For this purpose, we have tried to optimize the use of three tumour markers determined on pleural effusions, to differentiate SCLC from NSCLC by means of a canonic variable, generated by discriminant analysis, including subjects with histologically proven lung cancer. Discriminant analysis was performed by using carcinoembryonic antigen, neuron-specific enolase and tissue polypeptide antigen pleural levels, determined in 65 consecutive and unselected patients, histologically classified as 49 NSCLC and 16 SCLC. To validate the formula generated, a control group of 37 lung cancer patients (10 SCLC and 27 NSCLC), enrolled subsequently, was employed. Applying the discriminant analysis to SCLC and NSCLC patients a good classification was obtained (92% rate of correct classification). The aforementioned formula, applied to the validation group, showed a 92% rate of correct classification. This method, which is rapid, inexpensive and routinely applicable to malignant pleural effusions, may be reliably used to classify lung cancer patients.

摘要

将肺癌分为小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC)对于疾病的预后和治疗至关重要。为此,我们试图优化对胸腔积液中测定的三种肿瘤标志物的使用,通过判别分析生成的一个典型变量来区分SCLC和NSCLC,纳入组织学确诊为肺癌的患者。对65例连续且未经选择的患者进行判别分析,这些患者组织学分类为49例NSCLC和16例SCLC,测定其癌胚抗原、神经元特异性烯醇化酶和组织多肽抗原的胸腔积液水平。为验证生成的公式,随后纳入了37例肺癌患者(10例SCLC和27例NSCLC)作为对照组。将判别分析应用于SCLC和NSCLC患者,获得了良好的分类结果(正确分类率为92%)。将上述公式应用于验证组,正确分类率为92%。这种方法快速、廉价且可常规应用于恶性胸腔积液,可可靠地用于肺癌患者的分类。

相似文献

4
Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study.
J Cancer Res Clin Oncol. 2013 Apr;139(4):557-62. doi: 10.1007/s00432-012-1357-1. Epub 2012 Dec 7.
6
WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
J Cancer Res Clin Oncol. 2009 Jul;135(7):919-24. doi: 10.1007/s00432-008-0527-7. Epub 2008 Dec 16.

引用本文的文献

1
Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions.
Br J Cancer. 1999 Nov;81(6):1059-65. doi: 10.1038/sj.bjc.6690807.

本文引用的文献

1
Diagnostic tests for lung cancer.
Mayo Clin Proc. 1993 Mar;68(3):288-96. doi: 10.1016/s0025-6196(12)60051-2.
2
Functional alterations accompanying a rapid decline in ventilatory function.
Am Rev Respir Dis. 1993 Feb;147(2):379-84. doi: 10.1164/ajrccm/147.2.379.
3
Pleural effusion in lung cancer.
Clin Chest Med. 1993 Mar;14(1):189-200.
4
Management of small-cell lung cancer.
Clin Chest Med. 1993 Mar;14(1):173-87.
9
Neuron-specific enolase.
Int J Biol Markers. 1994 Oct-Dec;9(4):205-10. doi: 10.1177/172460089400900401.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验